Body's own defense against H. pylori, cause of stomach ulcers and stomach cancer

August 12, 2004

(La Jolla, California) An international team led by The Burnham Institute's Minoru Fukuda, Ph.D., has discovered that a human glycoprotein inhibits Helicobacter pylori ("H. pylori"), the bacterium that causes stomach ulcers and is linked with 90% of stomach cancers. Published on August 13th in Science magazine, these results present a new way of looking at treating chronic inflammation associated with stomach ulcers, and introduces the possibility of preventing stomach cancer associated with H. pylori.

Over fifty percent of the world's population is infected with H. pylori, yet only 2% are afflicted with stomach ulcers and only 1% with stomach cancer. A collaboration between The Burnham Institute and Japan's Shinsu University has discovered the defense mechanism that protects the stomach against H. pylori infection.

H. pylori is found in mostly in the stomach, where it thrives in the superficial mucin layer lining the stomach. The bacterium is rarely found in the deeper portion of the mucin layer, where the mucous cells produce a particular class of glycoproteins, called O-glycans, linked with the carbohydrate alpha 1,4-N-acetylglusoseamine, cloned previously in Dr. Fukuda's laboratory.

Because the alpha 1,4-linked N-acetylgucosamine is confined to the stomach's deeper mucosa lining, which also lacks H. pylori, the scientists investigated the possibility that it might play a role against infection by H. pylori.

They isolated mucin from the upper and lower layers and found a key difference: surface-derived mucin actively supported H. pylori growth, while mucins from the second layer inhibited growth. H. pylori in the presence of alpha 1,4-linked N-acetylgucosamine lost its shape, became immobile, and eventually died. This cell-growth immobilizing effect is very similar to the effect of antibiotics, which dissolve or "lyse" the bacterium's cell wall.

The researchers lysed H. pylori cells and set up a biochemical assay using mass spectrometry to analyze the bacterium's cell wall components. They discovered a cholesterol unique to H. pylori, cholesteryl-alpha-D-glucopyranoside, which is a major component of the bacterium's cell wall and essential element to its growth.

Further experiments confirmed that the O-glycans capped with alpha 1,4-linked N-acetylglucosamine blocked H. pylori's ability to synthesize the cholesterol.

"This is the first time that a glycoprotein has been shown to behave like an antibiotic," says Dr. Minoru Fukuda, who has devoted 20 years of his research career to the study of glycobiology and cancer. "This naturally-occurring cholesterol offers a very specific target for the design of safer drugs that could treat stomach ulcers and, long-term, prevent stomach cancer linked with H. pylori."

Dr. Fukuda believes that it will be possible to breed cows and genetically engineered soy beans from which it would be possible to produce milk bearing the inhibitory O-glycans capped with alpha 1,4-linked N-acetylglucosamine. This offers an inexpensive way to help people suffering in less developed countries.

Says Dr. Fukuda, "If we could use transgenic cows and plants to produce this milk, we could completely eradicate H. pylori infection, and we can eliminate stomach cancer".
The Burnham Institute has applied for patents based on this work.

Dr. Minoru Fukuda is a Professor in Glycobiology Program of The Burnham Institute's Cancer Center. Other co-authors from The Burnham Institute include Dr. Michiko Fukuda, Professor, and Dr. Motohiro Kobayashi, postdoctoral fellow.

This work was done in collaboration with Dr. Jun Nakayama, corresponding author, and Drs. Masatomo Kawakubo, Yuki Ito, Yukie Okimura, Kyoko Sakura, Susumu Kasama, and Tsutomu Katsuyama of Shinsu University, Japan.

This research was supported by grants from the National Cancer Institute and the Department of Defense.

The Burnham Institute is an independent, nonprofit, public benefit organization dedicated to basic biomedical research principally in the areas of cancer, neurosciences, aging, infectious and inflammatory diseases. The Institute ranks consistently among the world's most influential research organizations for the impact of its research in analyses conducted annually by the Institute for Scientific Information.

Sanford-Burnham Prebys Medical Discovery Institute

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to